Lenvatinib and a programmed cell death protein 1 (PD-1) inhibitor combined with TACE has shown great promise in patients with initially unresectable HCC for a conversion surgery as compared to initial surgery. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.